Trial Profile
Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CILI
- 23 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.
- 03 Mar 2021 Planned End Date changed from 1 Dec 2017 to 1 Dec 2022.